Balentine LLC’s Guardant Health GH Stock Holding History

Balentine LLC’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-122	Closed	-$10K	–	437
2020 Q2	$10K	Buy	+122	New	+$9.83K	﹤0.01%	556

Other funds holding GH

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Balentine LLC's GH Position: Q3 2020 in Review

Balentine LLC sold out of Guardant Health (GH) in Q3 2020, closing a stake of 122 shares — an estimated $10K sold.

Balentine LLC first reported a position in GH in Q2 2020 and held it in 1 quarter. The position peaked at $10K in Q2 2020. 346 funds tracked by Wall St. Rank hold GH as of Q3 2020.

Balentine LLC reported no remaining Guardant Health position as of Q3 2020 after selling out during the quarter.
Balentine LLC sold 122 Guardant Health shares in Q3 2020, an estimated $10K.
Balentine LLC first reported a position in Guardant Health in Q2 2020 and held it in 1 quarter.
Balentine LLC's Guardant Health position peaked at $10K in Q2 2020.
346 funds tracked by Wall St. Rank held Guardant Health as of Q3 2020.

Based on Balentine LLC's 13F filing for Q3 2020, filed 2 Nov 2020.